{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-114996","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.936170+00:00","generated_at":"2026-06-08T15:46:37.336897+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rhythm Pharma Q3 IMCIVREE revenue $22.5M, net loss $44.2M; Phase 3 hypothalamic obesity on track","bullets":["Q3 2023 net product revenue from IMCIVREE $22.5M vs $4.3M in Q3 2022; 80% from U.S.","Net loss of $44.2M ($0.76 per share) vs $40.9M loss ($0.79 per share) in Q3 2022.","Phase 3 hypothalamic obesity trial expects full enrollment by end of 2023; 25.5% mean BMI reduction at 1 year in long-term extension (n=12).","Cash & investments $299.3M as of Sep 30, 2023, sufficient to fund operations into 2026.","Company expects 2023 Non-GAAP operating expenses $210M-$220M (R&D $125M-$130M, SG&A $85M-$90M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-114996","json":"https://secwatch.observer/filing/0001104659-23-114996.json","markdown":"https://secwatch.observer/filing/0001104659-23-114996.md","text":"https://secwatch.observer/filing/0001104659-23-114996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923114996/0001104659-23-114996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923114996/tm2329850d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T15:46:37.336897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb5b22fa14c2e5b695b9d5d2193c9f34c6a4d6ac","claim":"RHYTHM PHARMACEUTICALS, INC. reported the third quarter ended September 30, 2023 results: revenue $22.5 million.","evidence_excerpt":"Third quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $22.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923114996/0001104659-23-114996-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$22.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}